CNN Central News & Network–ITDC India Epress/ITDC News Bhopal: Several major pharmaceutical companies in the U.S. have announced initiatives to sell drugs directly to consumers and implement significant price reductions, aligning with President Donald Trump’s push to lower prescription drug costs and eliminate intermediaries like pharmacies and insurers. This move follows the administration’s plan to launch TrumpRx.gov in early 2026, a government-run website aimed at offering reduced prices for prescription medications.
Notable companies participating include:
AstraZeneca: Signed a deal on October 10 to sell discounted medications through the TrumpRx website, offering up to 80% off certain drugs.
Bristol-Myers Squibb: Announced price cuts for blood clot treatment Eliquis and plaque psoriasis drug Sotyktu, with Sotyktu offered at over 80% off the list price.
Eli Lilly: Began shipping the two highest doses of its weight-loss drug Zepbound directly to cash-paying customers in August.
Merck KGaA: Entered a deal on October 16 to sell fertility treatments directly to consumers with an 84% discount if used in IVF.
Novo Nordisk: Started offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients.
These initiatives aim to make prescription drugs more affordable and accessible to U.S. patients.
#PharmaCompanies #DirectToConsumerSales #PriceCuts #USHealthcare #TrumpAdministration #PrescriptionDrugs #AstraZeneca #BristolMyersSquibb #EliLilly #MerckKGaA #NovoNordisk
